TP53 and ovarian carcinoma: Presence of wild-type p53, on the other hand, does not necessarily ensure a chemosensitive phenotype, and a clinical study has underscored this very convincingly reporting that, among the group of chemoresistant ovarian tumors, 37% had wild-type p53 and 63% had mutant p53. The study also reports that loss of p53 function has been associated with the lack of response to high-dose cisplatin in ovarian cancer patients [10].